Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio is a preclinical stage biotechnology company with a promising technology stack utilizing AI-guided epitope-steering and monoclonal antibody optimization to minimize development risks, and its anti-Activin E antibody for obesity and cardiometabolic disease, IBIO-610, reported near-complete inhibition of Activin E after 8 weeks with positive clinical data compared to competitors. With multiple clinical asset candidates and a strong development pipeline, iBio faces competition and risks associated with clinical trials; however, with a probability of success of 5-20% and a WACC of 17%, our NPV analysis establishes our 12-month price target of $5 per share to capture the upside potential.

Bears say

iBio is highly dependent on future fundraising and their limited revenue-generating products puts them at risk of not achieving their target stock price. Additionally, legal expenses, competition, and potential infringement lawsuits could have a negative impact on their financial performance and valuation. Along with the potential need for future fundraising and potential dilution of stockholders, these factors should be taken into consideration by investors when evaluating iBio's stock.

iBio (IBIO) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 5 analysts, iBio (IBIO) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.